Last reviewed 2026-04-20 · How we verify

Doxil, Paclitaxel, Cyclophosphamide, Avastin

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Nausea
• Alopecia
• Peripheral sensory neuropathy
• Constipation
• Myalgia
• Headache
• Arthralgia
• Blood disorder
• Vomiting
• Nail disorder
• Insomnia

Key clinical trials

• Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (PHASE3)
• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (PHASE2)
• QUILT-3.088: NANT Pancreatic Cancer Vaccine (PHASE2)
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
• Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer (PHASE2)
• A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer (PHASE2)
• Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer (PHASE2)
• Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Doxil, Paclitaxel, Cyclophosphamide, Avastin CI brief — competitive landscape report
• Doxil, Paclitaxel, Cyclophosphamide, Avastin updates RSS · CI watch RSS
• University of Alabama at Birmingham portfolio CI